Related Experiment Video
Updated: Jun 14, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348
Tracy E Macaulay1, Christopher Allen, Khaled M Ziada
1University of Kentucky, Gill Heart Institute, Division of Cardiovascular Medicine, 900 South Limestone, 326 Wethington Building, Lexington, KY 40536-0200, USA.
Insights
A new antiplatelet drug, SCH 530348, targets thrombin-mediated platelet activation via proteinase-activated receptor-1 (PAR-1) antagonism. Early studies suggest it may offer improved antithrombotic protection with reduced bleeding risk, pending Phase III trial confirmation.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Thrombosis Research
Background:
- Coronary artery disease (CAD) remains a major global health burden, with platelet activation central to its progression and acute coronary syndromes (ACS).
- Current antiplatelet therapies, while effective, have limitations, necessitating novel agents with improved efficacy and safety profiles.
- Inhibition of proteinase-activated receptor-1 (PAR-1), a key mediator of thrombin-induced platelet activation, represents a promising therapeutic strategy.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, and clinical development of SCH 530348, a novel PAR-1 antagonist.
- To evaluate the potential of SCH 530348 as an adjunctive antiplatelet therapy in atherothrombotic disease.
- To summarize current clinical data and discuss the future applications of SCH 530348 in cardiovascular prevention.
Main Methods:
- Comprehensive literature review of publications on SCH 530348 over the past decade.
- Analysis of data from Phase II clinical trials assessing SCH 530348's efficacy and safety.
- Examination of ongoing Phase III trials for patients with ACS and secondary prevention.
Main Results:
- SCH 530348 is an orally administered PAR-1 antagonist with a novel mechanism of action.
- Phase II trials suggest SCH 530348 may provide additional antithrombotic benefits when added to existing antiplatelet regimens.
- Early data indicate a potentially lower risk of bleeding compared to current therapies.
Conclusions:
- SCH 530348 represents a new class of antiplatelet agent targeting thrombin-mediated platelet activation.
- While early clinical data are encouraging regarding safety and potential efficacy, definitive confirmation awaits results from ongoing Phase III trials.
- The efficacy of SCH 530348 in improving clinical outcomes for patients with coronary disease requires further validation.
Importance Of The Field:
Coronary artery disease is a leading cause of morbidity and mortality worldwide. Platelet activation and subsequent thrombus formation play a central role in disease progression and development of acute coronary syndromes (ACS). Despite widespread use of single and dual antiplatelet therapies in atherothrombotic disease, ischemic complications remain common. Therefore, the need exists for new antiplatelet agents that are more effective, but with acceptable safety profiles (i.e., do not increase risk of bleeding). Antiplatelet agents available at present are effective in blocking the cyclo-oxygenase, ADP-mediated and final common (IIb/IIIa receptor) pathways for platelet activation. Recently, there has been more interest in inhibition of the proteinase-activated receptor-1 (PAR-1), which blocks thrombin-mediated platelet activation.
Areas Covered In This Review:
This review covers the pharmacology, pharmacokinetics and development of the new PAR(1) antagonist, SCH 530348 in a review of all publications relevant to the topic over the last 10 years. Phase II clinical trials indicate that addition of this agent to current antiplatelet regimens may provide additional antithrombotic protection without an increase in bleeding. Results of the ongoing Phase III trials, examining the use of SCH 530348 in patients with ACS and for secondary prevention of ischemic events are anxiously awaited.
What The Reader Will Gain:
The review is a summary of all pharmacologic properties and current clinical data available on the PAR1 antagonist SCH 530348. The readers will be introduced to its novel mechanism of action, advantages over current antiplatelet agents and potential future applications should ongoing clinical trials confirm its efficacy in reducing platelet activity.
Take Home Message:
SCH 530348 is a new, orally administered antiplatelet agent that blocks the protease-activated thrombin receptor on the platelet. Early clinical data indicate that it is associated with a lower risk of bleeding. However, its efficacy in improving clinical outcomes in patients with coronary disease remains to be confirmed in ongoing Phase III clinical trials.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:30Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...